Shares of TG Therapeutics (NASDAQ:TGTX) remained unaffected after the company reported Q1 results.
Earnings per share were down 43.75% year over year to ($0.69), which missed the estimate of ($0.49).
Revenue of $793,000 up by 1986.84% year over year, which beat the estimate of $650,000.
TG Therapeutics hasn't issued any earnings guidance for the time being.
Revenue guidance hasn't been issued by the company for now.
Conference Call Details
Date: May 10, 2021
Time: 08:30 AM
52-week high: $56.74
52-week low: $16.56
Price action over last quarter: down 5.92%
TG Therapeutics Inc is a biopharmaceutical company. It is engaged in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company is developing two therapies targeting hematologic malignancies. TG-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a unique epitope on the CD20 antigen found on mature B-lymphocytes. It is also developing TGR-1202 (umbralisib), an orally available PI3K delta inhibitor.